Cellectar Biosciences, Inc. — Q3 2015 Form 10-Q
Reporting period: Three and nine months ended September 30, 2015. Cellectar is a clinical-stage biopharmaceutical company developing phospholipid ether-drug conjugates for cancer treatment and imaging. It reported no product revenue and remains dependent on external financing.
Financial results and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $1.168 million | $1.470 million | $4.195 million | $4.566 million |
| General and administrative | $835,000 | $803,000 | $2.596 million | $2.850 million |
| Total costs and expenses | $2.093 million | $2.273 million | $6.971 million | $7.638 million |
| Net income (loss) | $(1.858) million | $324,000 | $(6.446) million | $(4.705) million |
| Net loss per share | $(0.25) | $0.06 | $(0.85) | $(1.31) |
- At September 30, cash and cash equivalents were $2.473 million, with $55,000 of restricted cash. Current assets were $2.973 million versus current liabilities of $5.476 million, a working-capital deficit of approximately $2.503 million.
- Total liabilities were $5.781 million and stockholders’ equity was $680,000. Notes payable totaled approximately $390,000, excluding capital lease obligations; the $4.651 million derivative liability represents warrants, not conventional borrowing.
- Operating cash use was $6.719 million for the first nine months, compared with $6.699 million in 2014. Investing cash use was $40,000; financing cash use was $192,000. Cash declined $6.950 million from year-end 2014.
- No meaningful operating margin is reported because the company had no revenue. Interest expense was approximately $1,000 for the nine-month period.
Changes versus the prior comparable period
- Q3 operating expenses fell about 8% year over year, mainly from lower R&D spending; G&A increased about 4%. The company recorded $90,000 of Q3 restructuring costs.
- For the first nine months, operating expenses fell about 9%. R&D declined approximately $371,000 and G&A declined approximately $254,000, partly offset by $180,000 of restructuring costs.
- Despite lower operating expenses, the nine-month net loss widened by approximately $1.741 million. The main comparison factor was a much smaller noncash gain from warrant revaluation: $526,000 in 2015 versus $3.369 million in 2014. In Q3, the corresponding gain was $234,000 versus $2.850 million, contributing to the shift from prior-year net income to a loss.
Outlook, risks and notable events
- Management expects continuing operating losses and stated that September cash plus approximately $2.868 million of net proceeds from an October 1, 2015 financing was expected to fund operations into the second quarter of 2016. Additional capital will be needed; no future financing was assured, and management reported no financing negotiations underway.
- The October financing generated $3.3 million gross proceeds through a registered offering and concurrent private placement. It included common shares, pre-funded warrants and warrants, with potential dilution and price-adjustment provisions. A stockholder meeting to seek required Nasdaq approval was scheduled for November 30, 2015.
- Nasdaq had notified the company of noncompliance because stockholders’ equity at June 30, 2015 was below the $2.5 million minimum. Nasdaq granted an extension to regain compliance and report in the 2015 Form 10-K; delisting remained a risk.
- The lead therapeutic, CLR 131, was in a Phase I study for relapsed/refractory multiple myeloma. The company anticipated evaluating the first cohort and initiating the second in the first half of 2016. Other chemotherapy candidates were preclinical. For CLR 1502, FDA classification as a combination product required a new investigational application, and the company was assessing the clinical pathway.
- Management concluded disclosure controls were not effective as of September 30 because of a material weakness in accounting for equity instruments. Remediation efforts were ongoing, with no assurance they would fully resolve the weakness.
- The filing identifies financing availability, clinical and regulatory development, product commercialization, and Nasdaq listing compliance as significant risks. It reports no legal proceedings expected to materially affect the financial statements.
Key facts for investors to verify
- Whether the October financing and subsequent warrant-related terms provide sufficient runway, and the timing and terms of any further capital raise.
- Whether the company regained Nasdaq’s stockholders’ equity compliance by the required annual-report deadline and obtained the stockholder approval related to the October offering.
- CLR 131 Phase I enrollment, safety findings, dose selection and progress against the anticipated 2016 cohort timing.
- Progress resolving the equity-accounting material weakness and improving disclosure controls.
- The sensitivity of reported earnings and liabilities to warrant valuation and anti-dilution provisions.